Lippman Evan sold TEVA
May 14, 2026 · Form 4 insider transaction
Lippman Evan sold 35,912 shares of Teva Pharmaceutical Industries Limited at $35.58 per share, a transaction worth $1.28M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.; The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.; Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.; The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.38 to $35.685, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.